ClinicalTrials.gg
TerminatedNCT00514917Rising PSAUpdated Nov 4, 2013Results posted

A Study of Androgen Deprivation With Leuprolide, +/- Docetaxel for Clinically Asymptomatic Prostate Cancer Participants With a Rising Prostate Specific Antigen (PSA)

A Phase 3 interventional study of Docetaxel and Leuprolide in Prostatic Neoplasms, sponsored by Sanofi. Terminated at 9 sites in 9 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-11-04.

Sponsored by Sanofi · Phase 3, Interventional, and Treatment

Why this study was terminated
Company decision to discontinue the study, not due to any safety or efficacy concerns

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
413
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 193 studies testing docetaxel in Prostatic Neoplasms — 15 open to participants now, 24 under way, 10 of them phase 3. Docetaxel · Prostatic Neoplasms.

Enrollment
14th of 185
413 · median 39
Started
2007
with 19 others
Phase 3
30 of 193
5 open now
Registered
94th of 193
by date
Lead sponsor
11 of 193
Sanofi

Among the 193 studies testing docetaxel in Prostatic Neoplasms, this one is the 14th largest by enrollment of the 185 interventional ones that give a count, is one of 20 that started in 2007, is one of 30 in phase 3, and was the 94th registered.

Prostatic Neoplasms

7,053 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

15 of the 193 studies testing docetaxel in Prostatic Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 15 open studies →

About docetaxel

Docetaxel: first FDA approval 1996 (TAXOTERE), first EMA approval 1995. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,233 Prostatic Neoplasms studies recruiting now, 931 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 193 studies testing docetaxel in Prostatic Neoplasms, or all of them as a file.
02

Study summary

The primary objective was to evaluate and compare the efficacy of androgen deprivation with or without docetaxel as determined by the median progression free survival (PFS) over the period of 18-month therapy and at least 18-month follow-up.

The secondary objectives were:

  • To assess cancer specific survival;
  • To compare overall survival between the 2 treatment groups;
  • To evaluate patient-reported outcomes including quality of life, fatigue, and sexual functioning as measured by 3 different assessments.
Read the detailed description

The duration of the study per participant was to be at least 36 months, of which the treatment period was 18 months for all participants, followed by at least 18 months follow-up period.

Participants received study treatment for up to 18 months from the time of study therapy initiation or less if one of the following occurred: disease progression, unacceptable toxicity, death, participant refusal or treatment delay beyond the time frame that is permitted for each treatment.

03

Conditions studied

  • Prostatic Neoplasms

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of prostate adenocarcinoma confirmed
  • History of radical prostatectomy (pre-operative radiation therapy to the prostate or pelvis or salvage radiation after radical prostatectomy was allowed)
  • Demonstration of biochemical progression of disease based on prostate specific antigen (PSA) doubling time. The minimum PSA value for eligibility was greater than or equal to (>=) 1. PSA doubling time over three values must be equal to (=) 9 months with a minimum of 3 weeks between assessments
  • Serum testosterone >=100 nanogram per deciliter (ng/dL)
  • performance status (KPS) >=70 percent (%)
  • Adequate organ function as defined by the following laboratory criteria:

    • White blood cells >=3500 per cubic millimeter (mm\^3)
    • (ANC) >=1500 per mm\^3
    • count >=100,000 per mm\^3
    • >= 10.0 gram per deciliter (g/dL)
    • Total less than or equal to (\<=) (ULN) unless due to Gilbert's disease
    • Creatinine l \<= 1.5 milligram per deciliter (mg/dL) or >=60 cubic centimeters per minute
    • (AST), alanine transaminase (ALT) and alkaline phosphatase within pre-defined ranges
  • Previous hormonal therapy was allowed provided that the total duration of therapy did not exceed 6 months
  • Man of who was willing to consent to use effective while on treatment and for at least 3 months thereafter
  • Participant who was willing and was able to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures

Exclusion criteria

Exclusion Criteria:

  • cardiac disease ( Class III/IV), or severe debilitating pulmonary disease
  • Uncontrolled serious active infection
  • Anticipated duration of life \< 2 years
  • Less than 5-year history of successful treatment for other cancers or concurrent active nonprostate cancer other than nonmelanoma dermatologic tumor
  • Peripheral neuropathy >=Grade 2
  • History of reaction to Docetaxel or other drugs formulated with polysorbate 80, leuprolide, or bicalutamide
  • Prior chemotherapy within the past 10 years (except non-taxane based chemotherapy for treatment of other cancers); concurrent treatment on another clinical trial or with any other cancer therapy including chemotherapy, immunotherapy, radiotherapy (except salvage radiation therapy), chemoembolization therapy, cryotherapy
  • Other severe acute or chronic medical conditions including psychiatric disease, or significant laboratory abnormality requiring further investigation that may cause undue risk for the participant's safety, delay or prohibit protocol participation, or interfere with the interpretation of study results, and in the judgment of the investigator would make the participant inappropriate for entry into this study
  • Radiographic findings suspicious for disease in the treating physician's clinical judgment. Participant who had radiographically suspicious pelvic lymph nodes prior to radial prostatectomy, but who, at the time of enrollment did not have suspicious adenopathy was eligible. Participant was eligible even if he/she had tumor-containing pelvic adenopathy at the time of surgery as long as at the time of enrollment there was no radiographically evident nodal disease in the clinician's opinion
  • Participant was the investigator or any sub-investigator, research assistant, pharmacist, study coordinator, other staff or relative thereof directly involved in the conduct of the protocol
  • Participant unlikely to comply with protocol or research tests, for example, uncooperative attitude, inability to return for follow-up visits, and unlikelihood of completing the study
  • Participant who participated in another clinical study/received product within 30 days of screening

The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
413 participants (actual)

Study arms

  • Experimental
    Docetaxel+Leuprolide+Bicalutamide

    Participants received docetaxel 75 milligram per square meter (mg/m\^2) intravenous infusion over 1 hour every 3 weeks up to 10 cycles (3 week cycle) along with leuprolide 22.5 mg injection subcutaneously every 12 weeks up to 18 months and bicalutamide 50 mg tablet orally once daily for first 4 weeks of treatment.

    Drug: Docetaxel · Drug: Leuprolide · Drug: Bicalutamide

  • Active comparator
    Leuprolide+Bicalutamide

    Participants received leuprolide 22.5 mg injection subcutaneously every 12 weeks up to 18 months and bicalutamide 50 mg tablet orally once daily for first 4 weeks of treatment.

    Drug: Leuprolide · Drug: Bicalutamide

Interventions

  • 75 mg/m\^2 intravenous infusion over 1 hour every 3 weeks up to 10 cycles.

    Also known as: TAXOTERE®, XRP6976

  • 22.5 mg injection subcutaneously every 12 weeks up to 18 months.

    Also known as: Eligard®

  • 50 mg tablet orally once daily for first 4 weeks of treatment.

06

What researchers measure

Primary outcomes

  1. Median Progression-Free Survival (PFS) in Intent-to-treat (ITT) Population

    PFS was the time from randomization to the date of first documented prostate specific antigen (PSA) progression, or radiographic progression, or death due to prostate cancer in the absence of previous documentation of disease progression, whichever occurred first. PSA progression was determined as: a) During treatment period: a 50 percent (%) increase from baseline, which was confirmed by a second value; b) During follow-up: detectable PSA (defined as PSA greater than or equal to 0.05 nanogram per millimeter \[ng/mL\]), which was confirmed by consecutive observation (not less than 2 weeks apart). Median PFS was estimated using the Kaplan-Meier method.

    Time frame: Randomization until PSA progression or radiographic progression or death due to prostate cancer, assessed up to Month 60

  2. Progression-Free Survival (PFS) Rate at Month 36 in ITT Population

    PFS rate at Month 36 was defined as probability of being progression-free at Month 36. PFS rate was estimated using the Kaplan-Meier method.

    Time frame: Month 36

  3. Median Progression-Free Survival (PFS) in Testosterone Specific Evaluable Population

    PFS was the time from randomization to the date of first documented PSA progression, or radiographic progression, or death due to prostate cancer in the absence of previous documentation of disease progression, whichever occurred first. Median PFS was estimated using the Kaplan-Meier method.

    Time frame: Randomization until PSA progression or radiographic progression or death due to prostate cancer, assessed up to Month 60

  4. Progression-Free Survival (PFS) Rate at Month 36 in Testosterone Specific Evaluable Population

    PFS rate at Month 36 was defined as probability of being progression-free at Month 36. PFS rate was estimated using the Kaplan-Meier method.

    Time frame: Month 36

Secondary outcomes

  1. Overall Survival (OS): Number of Participants Who Died (All Cause)

    The OS was the time interval from the date of randomization to the date of death due to any cause. OS was to be analyzed using the Kaplan-Meier method. However, the analysis was not performed due to insufficient number of events. Reported is the number of participants who died from any cause.

    Time frame: Randomization until death due to any cause, assessed up to Month 60

  2. Cancer-Specific Survival: Number of Participants Who Died (Cancer-Specific)

    The cancer-specific survival was the time from the date of randomization to the date of death due to prostate cancer. Cancer-specific survival was to be analyzed using the Kaplan-Meier method. However, the analysis was not performed due to insufficient number of events. Reported is the number of participants who died from prostate cancer.

    Time frame: Randomization until death due to prostate cancer, assessed up to Month 60

  3. Change From Baseline in Functional Assessment of Cancer Therapy-Prostate (FACT-P) Total Score at End of Treatment (EOT)

    FACT-P is a 39-item participant questionnaire which assesses physical well-being (7 items), social/family well-being (7 items), emotional well-being (6 items), functional well-being (7 items), and additional prostate cancer specific concerns (12 items). All items are scored from 0 (not at all) to 4 (very much). The total FACT-P score ranges from 0-156, with higher scores representing a better quality of life with fewer symptoms. A score of 156 represents the best outcome.

    Time frame: Baseline, EOT (up to Month 18)

  4. Change From Baseline in Functional Assessment of Cancer Therapy-Prostate (FACT-P) Trial Outcome Index (TOI) Score at EOT

    Physical well-being, functional well-being, and prostate cancer concerns sub-scales of the FACT-P questionnaire were combined to calculate TOI. Total TOI score ranges from 0 to 104, with higher scores representing a better quality of life with fewer symptoms.

    Time frame: Baseline, EOT (up to Month 18)

  5. Change From Baseline in Multidimensional Assessment of Fatigue (MAF) Index Score at EOT

    MAF scale consists of 16-items to measure 4 dimensions of fatigue during past week: severity (Item 1-2), distress (Item 3), degree of interference in activities of daily living (Item 4-14), and timing (Item 15-16). Item 1-14 are scored on a numeric rating scale from 1 to 10, where higher score indicate more severity/distress/interference. Item 15-16 had multiple choice responses (4 responses each). Scale Index was calculated using Item 1-15, in following steps: 1) Item 15 score converted to 1-10 scale by multiplying the score with 2.5; 2) Average score was calculated from Item 4-14; 3) Finally scale index was calculated by adding Items 1, 2, 3 scores with average score from step 2 and converted score of Item 15 from step 1. Total MAF scale index score ranges 1 (no fatigue) to 50 (severe fatigue).

    Time frame: Baseline, EOT (up to Month 18)

  6. Change From Baseline in Erectile Function Domain of International Index of Erectile Function (EF-IIEF) Total Score at EOT

    EF-IIEF is a 6-item erectile function domain of IIEF. It consists of Question 1, 2, 3, 4, 5, and 15 of IIEF questionnaire. 5 questions are scored from 0 (no activity) to 5 (very high activity) and 1 question is scored from 1 (very low activity) to 5 (very high activity). Total EF-IIEF score ranges from 1 to 30, where higher score indicates high activity.

    Time frame: Baseline, EOT (up to Month 18)

Other outcomes

  1. Number of Participants With Treatment-Emergent Adverse Events (TEAEs)

    TEAE: any adverse event (AE) that occurred or worsened during the on-treatment period, which was the period from first administration of study treatment until 30 days after last administration of study treatment. AE: any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Serious AE: an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly, or medically important. Drug-related AEs were any untoward medical occurrences attributed to study drug in a participant who received study drug. National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 3.0 Grade 3 (severe) and Grade 4 (life threatening/disabling) TEAEs were also reported.

    Time frame: From first administration of study treatment until 30 days after the last administration of study treatment

07

Results

Posted Nov 4, 2013

Participant flow

Participants were enrolled from 53 sites in North America (the United States of America and Canada) and Europe. Study was terminated after all participants had completed treatment with docetaxel, but before all participants had completed 18 months follow-up. The termination was not due to any safety or efficacy concerns.

Participant flow — Overall Study
MilestoneDocetaxel+Leuprolide+BicalutamideLeuprolide+Bicalutamide
Started207206
Treated196204
Completed study treatment170182
Testosterone-specific evaluable122124
Completed8191
Not completed126115
Withdrew: Death410
Withdrew: Protocol violation10
Withdrew: Lost to follow-up43
Withdrew: Withdrawal by subject1816
Withdrew: Discontinued due to study closure8881
Withdrew: Undefined115

Outcome measures

PrimaryMedian Progression-Free Survival (PFS) in Intent-to-treat (ITT) Population

PFS was the time from randomization to the date of first documented prostate specific antigen (PSA) progression, or radiographic progression, or death due to prostate cancer in the absence of previous documentation of disease progression, whichever occurred first. PSA progression was determined as: a) During treatment period: a 50 percent (%) increase from baseline, which was confirmed by a second value; b) During follow-up: detectable PSA (defined as PSA greater than or equal to 0.05 nanogram per millimeter \[ng/mL\]), which was confirmed by consecutive observation (not less than 2 weeks apart). Median PFS was estimated using the Kaplan-Meier method.

Time frame:
Randomization until PSA progression or radiographic progression or death due to prostate cancer, assessed up to Month 60
Reported as:
Median · months
Median Progression-Free Survival (PFS) in Intent-to-treat (ITT) Population
monthsDocetaxel+Leuprolide+BicalutamideLeuprolide+Bicalutamide
Median Progression-Free Survival (PFS) in Intent-to-treat (ITT) Population25.4 (23.8 to 27.8)23.3 (22.6 to 25.1)
Statistical analysis
  • Docetaxel+Leuprolide+Bicalutamide vs Leuprolide+Bicalutamide · Log Rank · p = 0.0501 (A priori threshold for statistical significance = 0.05) · Hazard ratio (hr): 1.29 · 95% CI 1.00 to 1.65The hazard ratio Leuprolide+Bicalutamide vs. Docetaxel+Leuprolide+Bicalutamide was estimated using an un-stratified Cox proportional hazards model. A hazard ratio \>1 indicates a lower risk of Docetaxel+Leuprolide, compared to Leuprolide.
PrimaryProgression-Free Survival (PFS) Rate at Month 36 in ITT Population

PFS rate at Month 36 was defined as probability of being progression-free at Month 36. PFS rate was estimated using the Kaplan-Meier method.

Time frame:
Month 36
Reported as:
Number · percent chance of being progression-free
Progression-Free Survival (PFS) Rate at Month 36 in ITT Population
percent chance of being progression-freeDocetaxel+Leuprolide+BicalutamideLeuprolide+Bicalutamide
Progression-Free Survival (PFS) Rate at Month 36 in ITT Population15.5 (9.1 to 23.3)8.6 (3.8 to 16.0)
SecondaryOverall Survival (OS): Number of Participants Who Died (All Cause)

The OS was the time interval from the date of randomization to the date of death due to any cause. OS was to be analyzed using the Kaplan-Meier method. However, the analysis was not performed due to insufficient number of events. Reported is the number of participants who died from any cause.

Time frame:
Randomization until death due to any cause, assessed up to Month 60
Reported as:
Number · participants
Overall Survival (OS): Number of Participants Who Died (All Cause)
participantsDocetaxel+Leuprolide+BicalutamideLeuprolide+Bicalutamide
Overall Survival (OS): Number of Participants Who Died (All Cause)411
SecondaryCancer-Specific Survival: Number of Participants Who Died (Cancer-Specific)

The cancer-specific survival was the time from the date of randomization to the date of death due to prostate cancer. Cancer-specific survival was to be analyzed using the Kaplan-Meier method. However, the analysis was not performed due to insufficient number of events. Reported is the number of participants who died from prostate cancer.

Time frame:
Randomization until death due to prostate cancer, assessed up to Month 60
Reported as:
Number · participants
Cancer-Specific Survival: Number of Participants Who Died (Cancer-Specific)
participantsDocetaxel+Leuprolide+BicalutamideLeuprolide+Bicalutamide
Cancer-Specific Survival: Number of Participants Who Died (Cancer-Specific)23
SecondaryChange From Baseline in Functional Assessment of Cancer Therapy-Prostate (FACT-P) Total Score at End of Treatment (EOT)

FACT-P is a 39-item participant questionnaire which assesses physical well-being (7 items), social/family well-being (7 items), emotional well-being (6 items), functional well-being (7 items), and additional prostate cancer specific concerns (12 items). All items are scored from 0 (not at all) to 4 (very much). The total FACT-P score ranges from 0-156, with higher scores representing a better quality of life with fewer symptoms. A score of 156 represents the best outcome.

Time frame:
Baseline, EOT (up to Month 18)
Reported as:
Mean · units on a scale
Change From Baseline in Functional Assessment of Cancer Therapy-Prostate (FACT-P) Total Score at End of Treatment (EOT)
units on a scaleDocetaxel+Leuprolide+BicalutamideLeuprolide+Bicalutamide
Baseline (n=206, 205)121.4 ± 18.32119.6 ± 17.95
Change at EOT (n=186, 184)-4.9 ± 13.55-3.4 ± 14.78
SecondaryChange From Baseline in Functional Assessment of Cancer Therapy-Prostate (FACT-P) Trial Outcome Index (TOI) Score at EOT

Physical well-being, functional well-being, and prostate cancer concerns sub-scales of the FACT-P questionnaire were combined to calculate TOI. Total TOI score ranges from 0 to 104, with higher scores representing a better quality of life with fewer symptoms.

Time frame:
Baseline, EOT (up to Month 18)
Reported as:
Mean · units on a scale
Change From Baseline in Functional Assessment of Cancer Therapy-Prostate (FACT-P) Trial Outcome Index (TOI) Score at EOT
units on a scaleDocetaxel+Leuprolide+BicalutamideLeuprolide+Bicalutamide
Baseline (n=206, 206)82.1 ± 12.5880.4 ± 12.52
Change at EOT (n=187, 187)-5.4 ± 10.19-3.1 ± 11.83
PrimaryMedian Progression-Free Survival (PFS) in Testosterone Specific Evaluable Population

PFS was the time from randomization to the date of first documented PSA progression, or radiographic progression, or death due to prostate cancer in the absence of previous documentation of disease progression, whichever occurred first. Median PFS was estimated using the Kaplan-Meier method.

Time frame:
Randomization until PSA progression or radiographic progression or death due to prostate cancer, assessed up to Month 60
Reported as:
Median · months
Median Progression-Free Survival (PFS) in Testosterone Specific Evaluable Population
monthsDocetaxel+Leuprolide+BicalutamideLeuprolide+Bicalutamide
Median Progression-Free Survival (PFS) in Testosterone Specific Evaluable Population25.7 (25.1 to 28.1)24.7 (22.8 to 25.3)
SecondaryChange From Baseline in Multidimensional Assessment of Fatigue (MAF) Index Score at EOT

MAF scale consists of 16-items to measure 4 dimensions of fatigue during past week: severity (Item 1-2), distress (Item 3), degree of interference in activities of daily living (Item 4-14), and timing (Item 15-16). Item 1-14 are scored on a numeric rating scale from 1 to 10, where higher score indicate more severity/distress/interference. Item 15-16 had multiple choice responses (4 responses each). Scale Index was calculated using Item 1-15, in following steps: 1) Item 15 score converted to 1-10 scale by multiplying the score with 2.5; 2) Average score was calculated from Item 4-14; 3) Finally scale index was calculated by adding Items 1, 2, 3 scores with average score from step 2 and converted score of Item 15 from step 1. Total MAF scale index score ranges 1 (no fatigue) to 50 (severe fatigue).

Time frame:
Baseline, EOT (up to Month 18)
Reported as:
Mean · units on a scale
Change From Baseline in Multidimensional Assessment of Fatigue (MAF) Index Score at EOT
units on a scaleDocetaxel+Leuprolide+BicalutamideLeuprolide+Bicalutamide
Baseline (n=168, 171)16.4 ± 7.3316.6 ± 7.93
Change at EOT (n=127, 144)4.0 ± 8.932.6 ± 8.60
PrimaryProgression-Free Survival (PFS) Rate at Month 36 in Testosterone Specific Evaluable Population

PFS rate at Month 36 was defined as probability of being progression-free at Month 36. PFS rate was estimated using the Kaplan-Meier method.

Time frame:
Month 36
Reported as:
Number · percent chance of being progression-free
Progression-Free Survival (PFS) Rate at Month 36 in Testosterone Specific Evaluable Population
percent chance of being progression-freeDocetaxel+Leuprolide+BicalutamideLeuprolide+Bicalutamide
Progression-Free Survival (PFS) Rate at Month 36 in Testosterone Specific Evaluable Population15.8 (9.0 to 24.3)9.1 (4.0 to 16.7)
SecondaryChange From Baseline in Erectile Function Domain of International Index of Erectile Function (EF-IIEF) Total Score at EOT

EF-IIEF is a 6-item erectile function domain of IIEF. It consists of Question 1, 2, 3, 4, 5, and 15 of IIEF questionnaire. 5 questions are scored from 0 (no activity) to 5 (very high activity) and 1 question is scored from 1 (very low activity) to 5 (very high activity). Total EF-IIEF score ranges from 1 to 30, where higher score indicates high activity.

Time frame:
Baseline, EOT (up to Month 18)
Reported as:
Mean · units on a scale
Change From Baseline in Erectile Function Domain of International Index of Erectile Function (EF-IIEF) Total Score at EOT
units on a scaleDocetaxel+Leuprolide+BicalutamideLeuprolide+Bicalutamide
Baseline (n=201, 205)6.4 ± 8.306.8 ± 8.25
Change at EOT (n=180, 186)-3.1 ± 7.15-3.3 ± 7.11
Other pre-specifiedNumber of Participants With Treatment-Emergent Adverse Events (TEAEs)

TEAE: any adverse event (AE) that occurred or worsened during the on-treatment period, which was the period from first administration of study treatment until 30 days after last administration of study treatment. AE: any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Serious AE: an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly, or medically important. Drug-related AEs were any untoward medical occurrences attributed to study drug in a participant who received study drug. National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 3.0 Grade 3 (severe) and Grade 4 (life threatening/disabling) TEAEs were also reported.

Time frame:
From first administration of study treatment until 30 days after the last administration of study treatment
Reported as:
Number · participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
participantsDocetaxel+Leuprolide+BicalutamideLeuprolide+Bicalutamide
Any TEAE188163
Any Serious AE4920
Any TEAE Resulting in Death01
Any TEAE Leading to any Treatment Discontinuation351
Any Grade 3-4 TEAE9422
Docetaxel Related TEAE183NA
Leuprolide Related TEAE109136
Bicalutamide Related TEAE5274
Any Treatment Related TEAE184136
Any Grade 3-4 Serious TEAE4314
Any TEAE Leading to Interruption of any Treatment771

Adverse events

Collected over From signature of the informed consent form up to the last visit in the study. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Docetaxel+Leuprolide+Bicalutamide—49/196 (25%)185/196 (94.4%)
Leuprolide+Bicalutamide—20/204 (9.8%)139/204 (68.1%)
Most frequent serious events
Showing 10 of 64
Most frequent serious events
EventDocetaxel+Leuprolide+BicalutamideLeuprolide+Bicalutamide
FEBRILE NEUTROPENIABlood and lymphatic system disorders11/1960/204
NEUTROPENIABlood and lymphatic system disorders9/1960/204
ATRIAL FIBRILLATIONCardiac disorders3/1961/204
PNEUMONIAInfections and infestations3/1960/204
DIABETES MELLITUSMetabolism and nutrition disorders2/1960/204
PULMONARY EMBOLISMRespiratory, thoracic and mediastinal disorders2/1961/204
ANGINA PECTORISCardiac disorders1/1962/204
COLON CANCERNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1962/204
ANAEMIABlood and lymphatic system disorders1/1960/204
ACUTE MYOCARDIAL INFARCTIONCardiac disorders1/1960/204
Most frequent other events
Showing 10 of 47
Most frequent other events
EventDocetaxel+Leuprolide+BicalutamideLeuprolide+Bicalutamide
HOT FLUSHVascular disorders82/196118/204
ALOPECIASkin and subcutaneous tissue disorders110/1963/204
FATIGUEGeneral disorders104/19658/204
OEDEMA PERIPHERALGeneral disorders66/19611/204
DIARRHOEAGastrointestinal disorders64/1967/204
NAUSEAGastrointestinal disorders56/19611/204
DYSGEUSIANervous system disorders51/1961/204
NAIL DISORDERSkin and subcutaneous tissue disorders50/1961/204
ARTHRALGIAMusculoskeletal and connective tissue disorders40/19617/204
NEUROPATHY PERIPHERALNervous system disorders37/1963/204

Baseline characteristics

Safety population included all randomized participants who received at least part of one dose of any of the study drugs.

Age Continuous
Age Continuous(years)Docetaxel+Leuprolide+BicalutamideLeuprolide+BicalutamideTotal
Mean65.2 ± 6.9764.0 ± 6.9764.6 ± 6.99
Age, Customized
Age, Customized(participants)Docetaxel+Leuprolide+BicalutamideLeuprolide+BicalutamideTotal
Less Than (<) 65 Years86 ± 43.9104 ± 51.0190
Greater Than or Equal to (>=) 65 to < 75 Years95 ± 48.589 ± 43.6184
>= 75 Years15 ± 7.711 ± 5.426
Sex: Female, Male
Sex: Female, Male(Participants)Docetaxel+Leuprolide+BicalutamideLeuprolide+BicalutamideTotal
Female000
Male196204400
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Docetaxel+Leuprolide+BicalutamideLeuprolide+BicalutamideTotal
Caucasian/White175184359
Black161329
Asian/Oriental101
Others4711
Body Surface Area (BSA)
Body Surface Area (BSA)(square meter (m^2))Docetaxel+Leuprolide+BicalutamideLeuprolide+BicalutamideTotal
Mean2.05 ± 0.1762.08 ± 0.1942.06 ± 0.186
Prior Radiation Therapy
Prior Radiation Therapy(participants)Docetaxel+Leuprolide+BicalutamideLeuprolide+BicalutamideTotal
Number6375138
08

Study locations

9 sites
  • Sanofi-Aventis Administrative Office
    Bridgewater, New Jersey 08807, United States
  • Sanofi-Aventis Administrative Office
    Diegem, Belgium
  • Sanofi-Aventis Administrative Office
    Laval, Canada
  • Sanofi-Aventis Administrative Office
    Prague, Czechia
  • Sanofi-Aventis Administrative Office
    Frankfurt, Germany
  • Sanofi-Aventis Administrative Office
    Vilnius, Lithuania
  • Sanofi-Aventis Administrative Office
    Warsaw, Poland
  • Sanofi-Aventis Administrative Office
    Bratislava, Slovakia
  • Sanofi-Aventis Administrative Office
    Barcelona, Spain
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2007, a primary completion of Sep 2012 and a completion of Sep 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2013, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 2, 2007
First posted
Aug 10, 2007
Start
Jul 2007
Primary completionActual
Sep 2012
CompletionActual
Sep 2012
Results first posted
Nov 4, 2013
Last update
Nov 4, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 4, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00514917
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Aug 10, 2007
Start date
Jul 2007
Primary completion
Sep 2012
Completion
Sep 2012
Results posted
Nov 4, 2013
Last update
Nov 4, 2013

Study contacts

Barrett Childs, MD
study director · Sanofi

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Docetaxel

Start the discussion